Edition:
India

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

1.67EUR
22 Jun 2018
Change (% chg)

€0.03 (+1.52%)
Prev Close
€1.64
Open
€1.64
Day's High
€1.67
Day's Low
€1.64
Volume
426,844
Avg. Vol
554,530
52-wk High
€4.06
52-wk Low
€1.40

Latest Key Developments (Source: Significant Developments)

Pharma Mar Requests Change Of Primary Endpoint In Atlantis Trial
Tuesday, 12 Jun 2018 

June 12 (Reuters) - Pharma Mar SA ::REQUESTS THE MODIFICATION OF PRIMARY ENDPOINT TO OVERALL SURVIVAL (OS) FOR THE ATLANTIS TRIAL.AMENDMENT WAS SUBMITTED TO FOOD AND DRUG ADMINISTRATION (FDA) AND OTHER COMPETENT AUTHORITIES TO CHANGE PRIMARY ENDPOINT OF ATLANTIS PHASE III TRIAL FROM PROGRESSION FREE SURVIVAL (PFS) TO OVERALL SURVIVAL.EXPECTS THE "TOP LINE" DATA TO READOUT IN THE H2 OF 2019 FOR LURBINECTEDIN PHASE II SMALL-CELL LUNG CANCER STUDIES.  Full Article

Pharma Mar Signs License Agreement For Aplidin With Pint Pharma International
Monday, 11 Jun 2018 

June 11 (Reuters) - Pharma Mar SA ::SIGNS COMMERCIALIZATION AND DISTRIBUTION LICENSE AGREEMENT FOR APLIDIN WITH PINT PHARMA INTERNATIONAL.SIGNS LICENSE DEAL IN ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLOMBIA, ECUADOR, MEXICO, PARAGUAY, PERU, URUGUAY AND VENEZUELA.PINT TO PAY UNDISCLOSED MILESTONE, ROYALTY PAYMENTS TO THE CO IN EXCHANGE FOR RIGHTS TO REGISTER, COMMERCIALIZE, DISTRIBUTE APLIDIN IN EACH OF THE FORESAID TERRITORIES.TO RETAIN EXCLUSIVE PRODUCTION RIGHTS AND TO SUPPLY FINISHED PRODUCT FOR CLINICAL AND COMMERCIAL USE.  Full Article

Pharma Mar Says Phase III Trial With Zepsyre In Resistant Ovarian Cancer Not Met Its Primary Endpoint
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - PHARMA MAR SA ::CORAIL PHASE III WITH ZEPSYRE IN RESISTANT OVARIAN CANCER HAS NOT MET ITS PRIMARY ENDPOINT.  Full Article

Pharma Mar Requests Re-Examination Process For Aplidin From EMA
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - PHARMA MAR SA ::REQUESTS PROCESS OF RE-EXAMINATION FOR APLIDIN FROM THE EUROPEAN MEDICINES AGENCY (EMA).AFTER FINALIZING RE-EXAMINATION PROCESS, EUROPEAN COMMISSION TO ISSUE FINAL VERDICT ON THE MARKETING AUTHORIZATION APPLICATION (MAA) FOR APLIDIN AROUND JUNE OR JULY.  Full Article

Pharma Mar Signs Distribution License Agreement For Aplidin In Israel
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - PHARMA MAR SA ::SIGNS COMMERCIALIZATION AND DISTRIBUTION LICENSE AGREEMENT FOR APLIDIN WITH MEGAPHARM IN ISRAEL.  Full Article

Pharma Mar Says CHMP Against Approving MAA Of Aplidin For Multiple Myeloma Treatment
Friday, 15 Dec 2017 

Dec 15 (Reuters) - PHARMA MAR SA ::THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ISSUES OPINION AGAINST APPROVAL OF THE MARKETING AUTHORIZATION APPLICATION (MAA) OF APLIDIN FOR TREATMENT OF RELAPSED MULTIPLE MYELOMA.AFTER OPINION OF CHMP, EUROPEAN COMMISSION TO ISSUE FINAL DECISION, EXPECTED IN MARCH OR APRIL, 2018.  Full Article

Pharma Mar says IDMC recommends Phase III trial with Zepsyre in small-cell lung cancer patients to continue
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - PHARMA MAR SA ::PHASE III TRIAL WITH ZEPSYRE IN SMALL-CELL LUNG CANCER PATIENTS (ATLANTIS) TO CONTINUE WITHOUT CHANGES ON POSITIVE RECOMMENDATION BY IDMC (INDEPENDENT DATA MONITORING COMMITTEE).  Full Article

Pharma Mar presents positive results from phase II study of lurbinectedin in Ewing's sarcoma
Monday, 13 Nov 2017 

Nov 13 (Reuters) - PHARMA MAR SA ::PRESENTS POSITIVE RESULTS FROM A PHASE II STUDY OF LURBINECTEDIN IN EWING´S SARCOMA.OBSERVED DISEASE CONTROL RATE AT 60 PERCENT, INCLUDING PARTIAL RESPONSES IN 12 PERCENT AND STABILIZATION IN 48 PERCENT OF CASES.‍​.  Full Article

Pharma Mar expects EMA not to approve its Aplidin for multiple myeloma treatment
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - PHARMA MAR SA ::SAID ON WEDNESDAY, EXPECTS AN OPINION RECOMMENDING AGAINST APPROVAL OF MARKETING AUTHORIZATION APPLICATION FOR APLIDIN FOR TREATMENT OF MULTIPLE MYELOMA FROM EUROPEAN MEDICINES AGENCY (EMA) BASED ON PRELIMINARY "TREND VOTE" FEEDBACK FROM AGENCY.FORMAL WRITTEN DECISION FROM EMA'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) IS EXPECTED FOLLOWING ITS DECEMBER 2017 MEETING (DEC 11 TO DEC 15).COMPANY DEEPLY SURPRISED ABOUT CHMP NEGATIVE TREND VOTE GIVEN RESULTS OF PHASE III TRIAL.CHMP NEGATIVE TREND VOTE WAS VERBALLY COMMUNICATED TO COMPANY BY EMA.  Full Article

Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - PHARMA MAR SA ::SIGNS LICENSING AGREEMENT WITH BORYUNG PHARM TO COMMERCIALIZE THE MARINE-DERIVED ANTICANCER DRUG ZEPSYR (LURBINECTEDIN), IF APPROVED, IN SOUTH KOREA.TO RECEIVE A NON-DISCLOSED UPFRONT PAYMENT AND TO BE ELIGIBLE FOR ADDITIONAL REMUNERATIONS UPON ACHIEVING REGULATORY AND SALES MILESTONES.TO RETAIN EXCLUSIVE PRODUCTION RIGHTS AND TO SELL THE PRODUCT TO BORYUNG PHARM FOR COMMERCIAL USE.ZEPSYRE IS CURRENTLY IN LATE-STAGE CLINICAL DEVELOPMENT FOR PLATINUM-RESISTANT OVARIAN CANCER AND FOR SMALL-CELL LUNG CANCER.  Full Article

BRIEF-Pharma Mar FY Net Loss Widens To 26.7 Mln Euros YoY

* FY NET LOSS 26.7 MILLION EUROS VERSUS LOSS 24.1 MILLION EUROS YEAR AGO